These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27284778)

  • 1. Ingenol mebutate for pigmented superficial basal cell carcinomas: evaluation by confocal microscopy.
    Monfrecola G; Scalvenzi M; Costa C; Cantelli M; Fabbrocini G
    G Ital Dermatol Venereol; 2019 Oct; 154(5):586-588. PubMed ID: 27284778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.
    Diluvio L; Bavetta M; Di Prete M; Orlandi A; Bianchi L; Campione E
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27860083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successfully treated superficial basal cell carcinomas with ingenol mebutate 0.05% gel: Report of twenty cases.
    Izzi S; Sorgi P; Piemonte P; Carbone A; Frascione P
    Dermatol Ther; 2016 Nov; 29(6):470-472. PubMed ID: 27550505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ingenol mebutate: an introduction.
    Fallen RS; Gooderham M
    Skin Therapy Lett; 2012 Feb; 17(2):1-3. PubMed ID: 22358305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial.
    Siller G; Rosen R; Freeman M; Welburn P; Katsamas J; Ogbourne SM
    Australas J Dermatol; 2010 May; 51(2):99-105. PubMed ID: 20546215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superficial basal cell carcinoma successfully treated with ingenol mebutate gel 0.05%.
    Cantisani C; Paolino G; Cantoresi F; Faina V; Richetta AG; Calvieri S
    Dermatol Ther; 2014; 27(6):352-4. PubMed ID: 25052730
    [No Abstract]   [Full Text] [Related]  

  • 7. Fast evaluation and monitoring of ingenol mebutate treatment of multiple basal cell carcinomas by in vivo hand-held reflectance confocal microscopy.
    Manubens E; Barreiro A; Bennassar A; Podlipnik S; Moreno N; Iglesias P; Malvehy J; Puig S
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e284-e286. PubMed ID: 27859830
    [No Abstract]   [Full Text] [Related]  

  • 8. A scarring reaction to the treatment of basal cell carcinoma with ingenol mebutate.
    Nguyen NM; Tremaine AM; Zachary CB
    Skinmed; 2014; 12(5):317-8. PubMed ID: 25632654
    [No Abstract]   [Full Text] [Related]  

  • 9. Ingenol Mebutate for Lentigo Maligna: A Case Report.
    Gadaldi K; Feldmeyer L; Yawalkar N; Hunger RE
    Dermatology; 2016; 232 Suppl 1():24-8. PubMed ID: 27513527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma.
    García-de-la-Fuente MR; Santacana M; Verdaguer J; Vilardell F; Garí E; Casanova JM
    Australas J Dermatol; 2020 May; 61(2):e200-e207. PubMed ID: 31944277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical pharmacotherapy for skin cancer: part I. Pharmacology.
    Micali G; Lacarrubba F; Nasca MR; Schwartz RA
    J Am Acad Dermatol; 2014 Jun; 70(6):965.e1-12; quiz 977-8. PubMed ID: 24831324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dermoscopy and reflectance confocal microscopy for monitoring the treatment of actinic cheilitis with ingenol mebutate gel: Report of three cases.
    Benati E; Pampena R; Bombonato C; Borsari S; Lombardi M; Longo C
    Dermatol Ther; 2018 Jul; 31(4):e12613. PubMed ID: 29687567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient.
    Mühlstädt M
    Dermatology; 2016; 232 Suppl 1():20-3. PubMed ID: 27513345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Successful treatment of Bowen disease with ingenol mebutate].
    Braun SA; Homey B; Gerber PA
    Hautarzt; 2014 Oct; 65(10):848-50. PubMed ID: 25217087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
    Erlendsson AM
    Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical therapies for periorbital cutaneous malignancies: indications and treatment regimens.
    Sullivan TJ
    Curr Opin Ophthalmol; 2012 Sep; 23(5):439-42. PubMed ID: 22828167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice.
    Cozzi SJ; Le TT; Ogbourne SM; James C; Suhrbier A
    Arch Dermatol Res; 2013 Jan; 305(1):79-83. PubMed ID: 22871992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful Treatment of Relapsing Bowen's Disease with Ingenol Mebutate: The Use of Dermoscopy to Monitor the Therapeutic Response.
    Mainetti C; Guillod C; Leoni-Parvex S
    Dermatology; 2016; 232 Suppl 1():9-13. PubMed ID: 27513936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers.
    Gupta AK; Paquet M
    J Cutan Med Surg; 2013; 17(3):173-9. PubMed ID: 23673300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological Effects of Ingenol Mebutate Gel in Moderate to Severe Actinic Fields Assessed by Reflectance Confocal Microscopy: A Phase I Study.
    Ulrich M; Lange-Asschenfeldt S; Skak K; Skov T; Østerdal ML; Röwert-Huber HJ; Zibert JR; Stockfleth E
    J Drugs Dermatol; 2016 Oct; 15(10):1181-1189. PubMed ID: 27741334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.